Genzyme buys SangStat for $600m
October 29, 2003Research and Development
US biotech company Genzyme is to buy SangStat, a California-based company whose lead product Thymoglobulin is a $77 million-a-year treatment …
Pfizer/Pharmacia mega-merger gains final clearance
October 29, 2003Sales and Marketing
The creation of a new pharmaceutical goliath is now just days away after Pfizer and Pharmacia received final regulatory clearance …
AstraZeneca prepares Crestor for battle
October 29, 2003Sales and Marketing
AstraZeneca's US salesforce is gearing up to launch its potential blockbuster cholesterol-reducing drug Crestor, after receiving a long-awaited FDA approval.Crestor …
Yamanouchi reinforces US future with GSK deal
October 29, 2003Sales and Marketing
Japanese pharma company Yamanouchi has struck a deal to co-market its forthcoming overactive bladder treatment with GlaxoSmithKline in the US. …
Exanta on NICE list ahead of marketing authorisation
October 29, 2003Sales and Marketing
AstraZeneca's Exanta is to be in NICE's next programme of appraisals even though the blood-thinning drug has not yet received …
Pharma upbeat on the future of online detailing
October 29, 2003Medical Communications e-detailing, survey
The UK pharma industry remains open-minded about using online detailing, but wants to see more evidence of its effectiveness, a …
Aventis sues generic rivals over Lovenox
October 29, 2003Sales and Marketing
Aventis has gone to court in the US to prevent generic versions of its second-biggest drug, blockbuster anti-thrombotic treatment Lovenox, …
BMJ puts industry relations under spotlight
October 29, 2003Sales and Marketing
Patients would benefit from less involvement between pharmaceutical companies and the medical profession, according to new research.A study of more …
Doctors ask for one more performance indicator
October 29, 2003An increasing disengagement of GPs from their primary care trusts is threatening to thwart the government's plans for an NHS …
Pre-clinical marketing: understanding need
October 29, 2003Research and Development marketing, pre-clinical
Since the modern pharmaceutical industry emerged, product development has been largely driven by science, with R&D seen almost exclusively as …
New SSRI inquiry to consider patient experiences
October 29, 2003Sales and Marketing
The Government has conceded to intense pressure to give patients input into a new inquiry on the safety of SSRI …
Pele keeps playing for Pfizer
October 29, 2003Sales and Marketing
Pele has signed up with Pfizer to continue his work on raising awareness of erectile dysfunction for the pharma company.The …
GSK international pharma chief leaves for Chiron
October 29, 2003Sales and Marketing Chiron, David Stout, GSK, Howard Pien
GlaxoSmithKline’s head of international pharmaceutical operations, Howard Pien, is to leave the company to become Chief Executive of Chiron.Mr Pien’s …
GSK pipeline fuelled by purchases
October 29, 2003Research and Development
GlaxoSmithKline leads the industry in licensing in new drugs, buying the rights to nearly twice as many products as its …
Latest content
FibroFind appoints Lee Borthwick as CEO
